IGSC, 20% (Immune Globulin Subcutaneous (Human) 20%)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IGSC, 20% (Immune Globulin Subcutaneous (Human) 20%), covering 2024-03-22 to 2024-03-22. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID) [Phase 3]